Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 14

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 14
---
 exercise of such warrants).

Common Stock

The material terms and provisions of our Common Stock are described under the caption “Description of Capital Stock” on page 16 of
the accompanying prospectus.

Warrants

The following summary of certain terms and provisions of the Warrants that are being offered hereby is not complete and is subject to, and
qualified in its entirety by, the provisions of the Warrants, the form of which will be filed as an exhibit to a Current Report on Form 8-K in connection with this offering and incorporated by reference into
the registration statement of which this prospectus supplement and the accompanying prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Warrant for a complete description of the terms and
conditions of the Warrants. The Series A Warrants and the Series B Warrants have substantially the same terms, except with respect to their duration as discussed below.

Exercise Price and Duration

Each Warrant
has an exercise price of $1.95 per share. The Series A Warrants will expire five and a half years after the first closing and the Series B Warrants will expire two years after the first closing of this offering. This prospectus supplement and the
accompanying prospectus also registers the shares of Common Stock issuable upon the exercise of the Warrants sold in this offering. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment
in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price, and also upon any distribution of assets, including cash, stock, or other property to our stockholders.

Exercisability

The Warrants will be
exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a
cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder’s Warrants to the extent that the holder would own more than 4.99% of the outstanding Common Stock immediately after
exercise, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s Warrants up to 9.99% of the number of shares of our
Common Stock outstanding immediately after giving